Version 1
: Received: 6 June 2020 / Approved: 7 June 2020 / Online: 7 June 2020 (09:28:09 CEST)
How to cite:
Wu, X.; Yuan, J.; Karim, M.R.; Wang, Y. Management of Myasthenia Gravis During COVID-19 Pandemic. Preprints2020, 2020060074. https://doi.org/10.20944/preprints202006.0074.v1
Wu, X.; Yuan, J.; Karim, M.R.; Wang, Y. Management of Myasthenia Gravis During COVID-19 Pandemic. Preprints 2020, 2020060074. https://doi.org/10.20944/preprints202006.0074.v1
Wu, X.; Yuan, J.; Karim, M.R.; Wang, Y. Management of Myasthenia Gravis During COVID-19 Pandemic. Preprints2020, 2020060074. https://doi.org/10.20944/preprints202006.0074.v1
APA Style
Wu, X., Yuan, J., Karim, M.R., & Wang, Y. (2020). Management of Myasthenia Gravis During COVID-19 Pandemic. Preprints. https://doi.org/10.20944/preprints202006.0074.v1
Chicago/Turabian Style
Wu, X., Md Rezaul Karim and Yun-Fu Wang. 2020 "Management of Myasthenia Gravis During COVID-19 Pandemic" Preprints. https://doi.org/10.20944/preprints202006.0074.v1
Abstract
The outbreak of COVID-19 has brought unprecedented risks and challenges to everyone in the world. Myasthenia gravis is an autoimmune disease of the nervous system. Infection can worsen it and cause severe symptoms such as myasthenia crisis and respiratory failure. At present, the pandemic of COVID-19 may promote the aggravation of patients with MG. This article focuses on the respiratory management of MG patients during the epidemic of COVID-19.
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
